At Virgin Money, Sophie led the UK Listing Authority prospectus approval process for the company’s IPO as a FTSE 250 within an impressive three years. During this time at Virgin Money, Sophie also led the legal aspects of other corporate finance deals in excess of £13BN in four years.
She is a Founding Member of Women Innovating Together in Healthcare, Boston Chapter, Advisory Board Member at the University of Notre Dame Kellogg Institute for International Studies and Chair of Sentebale, a charity founded by Prince Harry, the Duke of Sussex, and Prince Seeiso to support children and young people affected by poverty, inequality and HIV/AIDS in southern Africa.
Prior to this, he was the Director of Early Pipeline Development at NASDAQ listed Tarsus Pharmaceuticals. Before this, he was at Oxford Science Enterprises (OSE) where he participated in over $350M of early stage venture capital investments, supported the growth and financing 55 early stage and supported the $160M Series B fundraise and preparations for the NASDAQ IPO of Vaccitech, inventor of the Oxford COVID-19 vaccine as a founding member of the OSE portfolio management team.
He holds a PhD from Oxford University where he was a Rhodes Scholar and a medical degree from the University of Cape Town (distinction and honours). He holds medical licenses in the United Kingdom and South Africa. He is a member of the board of directors of AMREF, a global Africa focused healthcare charity.
His experience covers the full range of drug development in a wide range of therapeutic areas; focusing on the transition from laboratory research to early clinical development. He has been principal investigator or sponsor of more than 100 clinical studies and expert contributor to approximately 20 marketing licence applications.
Employed roles have included Chief Medical Officer at Adiga Life Sciences and at Prosonix, both Oxford, UK; European Medical Leader and Global Safety Expert, Johnson and Johnson Corporate R&D; Global Program Director, Clinical Pharmacology & Discovery Medicine, GlaxoSmithKline Corporate R&D. He is a member of the American College of Chest Physicians and a Fellow of the Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians, UK.
Julia has over 24 years of experience as a finance professional with an established record of supporting biotech companies from start up through to exit, assisting in securing and then the management of over £200M of venture capital funds, strong skills in software implementation and accounting processes to aid the performance of ambitious businesses.
Since 2012, Julia has assisted the Institute of Manufacturing at Cambridge University by delivering a finance module for senior managers within a large global manufacturing business as part of a tailor-made MBA management programme.